Hikal Ltd (HIKAL) is currently trading at 213.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Hikal Limited manufactures active pharmaceutical ingredients, intermediates, specialty chemicals, crop-protection products, and contract development and manufacturing solutions for global customers. Its operations span Pharmaceuticals, Crop Protection, Animal Health, Personal Care, and related specialty-chemical opportunities, supported by five Indian manufacturing facilities, global offices, regulatory approvals, and an integrated research and technology platform. The company delivered a notable operational recovery in Q2 FY27: revenue increased 36% year-on-year to ₹434 crore, EBITDA rose to ₹45 crore, and margin expanded to 10.3%. However, Hikal Limited remained loss-making at the net level, with a ₹6 crore consolidated loss, highlighting the continuing burden of depreciation, interest, and underutilised capacity. Pharmaceuticals became the principal growth engine, with Q2 revenue rising 47% year-on-year to ₹278 crore and EBIT improving to ₹13 crore. Recovery in established APIs, new-product commercialisation, and CDMO execution supported the improvement, while the pipeline expanded across the United States, Europe, and Japan, including programmes at development, proposal, and RFP stages. Crop Protection revenue grew 21% year-on-year, but the segment remained loss-making because of elevated raw-material and energy costs, deferred demand, and Chinese pricing pressure. Hikal Limited nevertheless signed a multi-year European agrochemical CDMO contract, increased Japanese customer engagement, and continued strengthening its own-product and alternate-supplier opportunity pipeline. Personal Care manufacturing has commenced at Panoli, creating a new growth platform focused on next-generation UV filters. Hikal Limited expects customer approvals and subsequent global launches to build the business, while Animal Health continues to grow and the company reiterates full-year guidance for mid-teens revenue growth and substantial profitability improvement.

Over the past 52 weeks, Hikal Ltd has traded between a low of ₹145.95 and a high of ₹260.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Hikal Ltd has a market capitalization of approximately 2,720.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Hikal Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -544.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,720.63 Cr, Hikal Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Hikal Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Hikal Ltd is -544.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Hikal Limited's board is scheduled to consider and approve the standalone and consolidated unaudited results on November 3, 2026. The results cover the quarter and half-year ended September 30, 2026.

Hikal’s 38th AGM is scheduled for Wednesday, September 23, 2026 at 11:30 a.m. (IST) and will be conducted via VC/OAVM, with the deemed venue as its registered office in Mumbai.

Hikal reported a standalone net loss of ₹7.5 crore (₹75 million) for the quarter ended June 30, 2026.

Hikal reported Q4 FY25 revenue of ₹552 crore and EBITDA of ₹123 crore, with EBITDA margin improving to about 22.4% (also cited as 22.3%).